Comment on alemtuzumab and inclusion body myositis

Brain

Volumn 133, Issue 5, 2010, Pages

  Greenberg, Steven A ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; VALGANCICLOVIR;

CLINICAL RESEARCH; CLINICAL TRIAL; FEASIBILITY STUDY; HUMAN; LETTER; MONOTHERAPY; MUSCLE STRENGTH; MYOSITIS; PRIORITY JOURNAL;

EID: 77951891599     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awp275     Document Type: Letter

References (7)

1. Dalakas MC. Inflammatory, immune, and viral aspects of inclusion-body myositis. Neurology 2006; 66 (Suppl 1): S33-8.
2. Dalakas MC. Interplay between inflammation and degeneration: using inclusion body myositis to study "neuroinflammation". Ann Neurol 2008; 64: 1-3.
3. Dalakas MC, Illa I, Leon-Monzon M. Viruses, immunodeficiency, and inclusion-body myositis. In: Askanas V, Serratrice G, Engel WK, editors. Inclusion-body myositis and myopathies. Cambridge: Cambridge University Press; 1998. p. 275.
4. Dalakas MC, Rakocevic G, McElroy B, Salajegheh M, Love MH, Shrader J, et al. Alemtuzumab (CAMPATH 1-H) therapy in sporadic inclusion body myositis (sIBM): a treatment trial in patients with established natural history data. Neurol 2007a; 68 (Suppl 1): A361.
5. Dalakas MC, Rakocevic G, McElroy B, Salajegheh M, Schmidt J, Harris-Love M, et al. Alemtuzumab (CAMPATH-1H) therapy in sporadic inclusion body myositis (sIBM) alters disease progression and suppresses endomysial inflammation. Ann Neurol 2007b; 62 (Suppl 11): S60-1.
6. Dalakas MC, Rakocevic G, Schmidt J, Salajegheh M, McElroy B, Harris-Love MO, et al. Effect of Alemtuzumab (CAMPATH 1-H) in patients with inclusion-body myositis. Brain 2009; 132: 1536-1544
7. Laine C, Horton R, DeAngelis CD, Drazen JM, Frizelle FA, Godlee F, et al. Clinical Trial Registration: looking back and moving ahead. JAMA 2007; 298: 93-94 (Pubitemid 47026775)